ArticleCureus2024
Exophytic Gastric Mass Posing a Diagnostic Dilemma: A Case of Mesenteric Fibromatosis.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenteric fibromatosis (MF) and gastrointestinal stromal tumor (GIST) are distinct types of lesions that are often mistaken for one another. Fibromatosis of the stomach is a rare condition that can be misdiagnosed as GIST, with MF accounting for only 0.3% of all tumors. Due to its rarity, accurately identifying and appropriately treating this condition poses a significant challenge. Here, we report a case of a 45-year-old female who presented with multiple episodes of vomiting after food intake. Initial radiological investigations suggested a diagnosis of GIST. However, histopathological examination of the surgical excision specimen confirmed fibromatosis with a keloid pattern. Beta-catenin is a key marker for MF; although immunohistochemistry markers were negative for beta-catenin in this case, it is important to note that beta-catenin positivity is observed in only 70-80% of cases. Differentiating these two distinct tumors can be challenging due to potential overlaps in clinical presentation, macroscopic appearance, and even histological features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.